(Immuno)proteasomes as therapeutic target in acute leukemia

Jacqueline Cloos, Margot Sf Roeten, Niels E. Franke, Johan van Meerloo, Sonja Zweegman, Gertjan Jl Kaspers, Gerrit Jansen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

25 Citaten (Scopus)

Samenvatting

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.

Originele taal-2Engels
Pagina's (van-tot)599-615
Aantal pagina's17
TijdschriftCancer and Metastasis Reviews
Volume36
Nummer van het tijdschrift4
DOI's
StatusGepubliceerd - 1 dec. 2017

Vingerafdruk

Duik in de onderzoeksthema's van '(Immuno)proteasomes as therapeutic target in acute leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit